文献速递脑血管病

MicroRNA-15a/16-1 Antagomir改善实验性卒中缺血性脑损伤

MicroRNA-15a/16-1 Antagomir Ameliorates Ischemic Brain Injury in Experimental Stroke.
PubMed 文献 · Stroke · 2017-05-25

该研究在成年雄性miR-15a/16-1敲除与野生型小鼠及尾静脉注射miR-15a/16-1抑制剂(antagomir,30 pmol/g)的C57 BL/6J小鼠中,进行1小时大脑中动脉闭塞及72小时再灌注。结果显示遗传缺失或静脉递送antagomir均显著减小脑梗死体积、降低脑含水量、改善神经功能结局,并下调促炎细胞因子、上调抗凋亡蛋白Bcl-2和Bcl-w。提示miR-15a/16-1簇是缺血性卒中的新型治疗靶点。

要点

  • 遗传缺失或静脉注射miR-15a/16-1 antagomir可减小卒中小鼠脑梗死体积。
  • 抑制miR-15a/16-1可降低脑含水量并改善神经功能结局。
  • 机制涉及下调促炎细胞因子及上调抗凋亡蛋白Bcl-2和Bcl-w。

核心结论

  • 药理学抑制miR-15a/16-1簇通过上调抗凋亡蛋白和抑制促炎分子减轻缺血性脑损伤。
  • miR-15a/16-1簇是缺血性卒中的新型治疗靶点。

研究设计与样本

  • 研究使用成年雄性miR-15a/16-1敲除与野生型小鼠,以及尾静脉注射miR-15a/16-1特异性抑制剂(antagomir,30 pmol/g)的成年雄性C57 BL/6J小鼠。
  • 所有小鼠接受1小时大脑中动脉闭塞及72小时再灌注,评估神经评分、脑梗死体积、脑含水量和神经行为测试。
  • 通过定量聚合酶链反应或ELISA检测主要促炎细胞因子,Western blotting检测抗凋亡蛋白。

主要发现

  • 遗传缺失miR-15a/16-1簇或静脉递送antagomir显著减小卒中小鼠脑梗死体积。
  • 上述干预显著降低脑含水量并改善神经功能结局。
  • 抑制miR-15a/16-1显著降低缺血脑区白介素-6、单核细胞趋化蛋白-1、血管细胞黏附分子1、肿瘤坏死因子α的表达。
  • 抑制miR-15a/16-1显著增加缺血脑区Bcl-2和Bcl-w水平。

临床怎么用

  • 该研究提示miR-15a/16-1簇可作为缺血性卒中潜在治疗靶点,但尚未进入临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Dysregulation of the miR-15a/16-1 cluster in plasma has been reported in patients with stroke as a potential biomarker for diagnostic and prognostic use. However, the essential role and therapeutic potential of the miR-15a/16-1 cluster in ischemic stroke are poorly understood. This study is aimed at investigating the regulatory role of the miR-15a/16-1 cluster in ischemic brain injury and insight mechanisms. METHODS: Adult male miR-15a/16-1 knockout and wild-type mice, or adult male C57 BL/6J mice injected via tail vein with the miR-15a/16-1-specific inhibitor (antagomir, 30 pmol/g), were subjected to 1 hour of middle cerebral artery occlusion and 72 hours of reperfusion. The neurological scores, brain infarct volume, brain water content, and neurobehavioral tests were then evaluated and analyzed. To explore underlying signaling pathways associated with alteration of miR-15a/16-1 activity, major proinflammatory cytokines were measured by quantitative polymerase chain reaction or ELISA and antiapoptotic proteins were examined by Western blotting. RESULTS: Genetic deletion of the miR-15a/16-1 cluster or intravenous delivery of miR-15a/16-1 antagomir significantly reduced cerebral infarct size, decreased brain water content, and improved neurological outcomes in stroke mice. Inhibition of miR-15a/16-1 significantly decreased the expression of the proinflammatory cytokines interleukin-6, monocyte chemoattractant protein-1, vascular cell adhesion molecule 1, tumor necrosis factor alpha, and increased Bcl-2 and Bcl-w levels in the ischemic brain regions. CONCLUSIONS: Our data indicate that pharmacological inhibition of the miR-15a/16-1 cluster reduces ischemic brain injury via both upregulation of antiapoptotic proteins and suppression of proinflammatory molecules. These results suggest that the miR-15a/16-1 cluster is a novel therapeutic target for ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yang X, Tang X, Sun P, et al. MicroRNA-15a/16-1 Antagomir Ameliorates Ischemic Brain Injury in Experimental Stroke. Stroke. 2017. PMID: 28546328. doi:10.1161/STROKEAHA.117.017284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。